Correspondence
Letter to the Editor: Immune-Mobilizing Monoclonal T-Cell Receptors: A Novel Addition in the HBV Armamentarium
Swati Charak M.Sc.,
Swati Charak M.Sc.
Department of Hepatology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
Search for more papers by this author Akash Roy M.D.,
Akash Roy M.D.
Department of Hepatology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
Search for more papers by this author Virendra Singh D.M.,
Virendra Singh D.M.
Department of Hepatology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
Search for more papers by this author
Swati Charak M.Sc.,
Swati Charak M.Sc.
Department of Hepatology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
Search for more papers by this author Akash Roy M.D.,
Akash Roy M.D.
Department of Hepatology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
Search for more papers by this author Virendra Singh D.M.,
Virendra Singh D.M.
Department of Hepatology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
Search for more papers by this author
First published: 21 November 2020
No abstract is available for this article.
References
- 1Fergusson JR, Wallace Z, Connolly MM, Woon AP, Suckling RJ, Hine DW, et al. Immune-mobilising monoclonal T cell receptors mediate specific and rapid elimination of hepatitis B-infected cells. Hepatology 2020 Aug 8. https://doi.org/10.1002/hep.31503. [Epub ahead of print]
- 2Meng Z, Chen Y, Lu M. Advances in targeting the innate and adaptive immune systems to cure chronic hepatitis B virus infection. Front Immunol 2019; 10:3127.
- 3Yang H, Buisson S, Bossi G, Wallace Z, Hancock G, So C, et al. Elimination of latently HIV-infected cells from antiretroviral therapy-suppressed subjects by engineered immune-mobilizing T-cell receptors. Mol Ther 2016; 24: 1913-1925.
- 4Gane E, Verdon DJ, Brooks AE, Gaggar A, Nguyen AH, Subramanian GM, et al. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study. J Hepatol 2019; 1: 900-907.
